{"id":5306,"date":"2022-10-23T15:30:00","date_gmt":"2022-10-23T14:30:00","guid":{"rendered":"https:\/\/catapult.org.uk\/?post_type=case_study&p=5306"},"modified":"2023-08-21T12:27:43","modified_gmt":"2023-08-21T11:27:43","slug":"establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies","status":"publish","type":"case_study","link":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/","title":{"rendered":"Establishing Stevenage as a global leader for cell and gene therapies"},"content":{"rendered":"\n
<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n

Establishing Stevenage as a global leader for cell and gene therapies<\/h1>\n\n\n\n
<\/div>\n\n\n
\n
\"\"<\/figure><\/div>\n\n\n
<\/div>\n\n\n\n
\n
\n

In 2014, Cell and Gene Therapy Catapult recognised that a lack of UK capacity to support the development and manufacture of advanced therapy medicinal products (ATMPs) would stifle progression and investment, leading to UK companies leaving the country for other global centres.<\/p>\n\n\n\n

In response the Catapult secured \u00a360 million of Government investment to build the Stevenage Manufacturing Innovation Centre (MIC), which underwent an expansion in 2020 supported by \u00a312 million from the Medicines Manufacturing Industrial Strategy Challenge Fund and \u00a33.36 million from European Regional Development Fund (ERDF).<\/p>\n\n\n\n

The facility has gone from strength to strength supporting the leading developers of ATMPs to progress their products towards market and in 2020\/21 alone the UK collaborators in the Stevenage MIC raised over \u00a30.5 billion in finance.<\/p>\n<\/div>\n\n\n\n

\n

Today the area is a globally recognised centre for cell and gene therapy businesses, and is home to 75% of UK cell and gene therapy developers and 60% of the UK Good Manufacturing Practice (GMP) footprint for these therapies. The cell and gene therapy campus in Stevenage supports over 1,000 jobs and is now home to over 45 companies.<\/p>\n\n\n\n

Prior to 2017 and opening of the Stevenage MIC, a total of \u00a3131 million had been collectively raised by companies on the campus. Subsequently between 2017 and 2020 a further \u00a32 billion has been collectively raised by companies on the campus.<\/p>\n\n\n\n

Stevenage was designated a Life Science Opportunity Zone by the Office of Life Sciences (OLS) in February 2020 and as High Potential Opportunity area by the Department of International Trade (DIT) in October 2020.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n \n \n <\/svg>\n

\n With one of the world\u2019s leading cell and gene therapy clusters<\/em>, the UK is an ideal location for us to establish our Centre of Excellence for cell and gene therapy.<\/em> <\/p>\n \n

\n Dr Frank Mathias<\/strong>
CEO of Rentschler Biopharma <\/div>\n \n \n
\n \n \n <\/svg>\n <\/div>\n <\/div>\n\n\n\n
<\/div>\n\n\n
\n \u00a31.5bn \n <\/span>\n\n \n\n
\n investment raised by companies from 2017 to 2020\n <\/div> <\/div>\n\n
<\/div>\n\n <\/div>
\n 1000+\n <\/span>\n\n \n\n
\n employees\n <\/div> <\/div>\n\n
<\/div>\n\n <\/div>
\n \n <\/span>\n\n \n\n
\n Home to more than 45 cell and gene therapy companies \n <\/div> <\/div>\n\n
<\/div> \n\n <\/div>
\n In 2020\n <\/span>\n\n \n\n
\n Stevenage was designated a Life Science Opportunity and High Potential Opportunity area\n <\/div> <\/div>\n\n
<\/div>\n\n <\/div>\n\n <\/div> \n\n <\/div>\n\n\n
<\/div>\n\n\n\n
\"\"<\/figure>\n\n\n\n

<\/p>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there. <\/p>\n","protected":false},"featured_media":5307,"template":"","meta":{"_external_link_checkbox":false,"_external_link":"","_event_date":"","_featured_case_study":false},"categories":[9],"tags":[61,63],"class_list":["post-5306","case_study","type-case_study","status-publish","has-post-thumbnail","hentry","category-cell-and-gene-therapy","tag-catapult-highlights","tag-leverage"],"yoast_head":"\nEstablishing Stevenage as a global leader for cell and gene therapies - The Catapult Network<\/title>\n<meta name=\"description\" content=\"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Establishing Stevenage as a global leader for cell and gene therapies - The Catapult Network\" \/>\n<meta property=\"og:description\" content=\"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"The Catapult Network\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-21T11:27:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Catapult_UK\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/\",\"url\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/\",\"name\":\"Establishing Stevenage as a global leader for cell and gene therapies - The Catapult Network\",\"isPartOf\":{\"@id\":\"https:\/\/catapult.org.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png\",\"datePublished\":\"2022-10-23T14:30:00+00:00\",\"dateModified\":\"2023-08-21T11:27:43+00:00\",\"description\":\"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.\",\"breadcrumb\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage\",\"url\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png\",\"contentUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/catapult.org.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Case Studies\",\"item\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Establishing Stevenage as a global leader for cell and gene therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/catapult.org.uk\/#website\",\"url\":\"https:\/\/catapult.org.uk\/\",\"name\":\"The Catapult Network\",\"description\":\"The Innovate UK Catapult Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/catapult.org.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Establishing Stevenage as a global leader for cell and gene therapies - The Catapult Network","description":"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/","og_locale":"en_GB","og_type":"article","og_title":"Establishing Stevenage as a global leader for cell and gene therapies - The Catapult Network","og_description":"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.","og_url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/","og_site_name":"The Catapult Network","article_modified_time":"2023-08-21T11:27:43+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1-1024x576.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Catapult_UK","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/","url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/","name":"Establishing Stevenage as a global leader for cell and gene therapies - The Catapult Network","isPartOf":{"@id":"https:\/\/catapult.org.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage"},"image":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png","datePublished":"2022-10-23T14:30:00+00:00","dateModified":"2023-08-21T11:27:43+00:00","description":"UK Government invested \u00a372m in the Cell and Gene Therapy Catapult centre in Stevenage. This has led to the creation of one of the leading cell and gene therapy clusters globally and brought \u00a31.5bn to the region through the 45 companies that are now investing there.","breadcrumb":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#primaryimage","url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png","contentUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2022\/08\/CGTC-1.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/establishing-stevenage-as-a-global-leader-for-cell-and-gene-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/catapult.org.uk\/"},{"@type":"ListItem","position":2,"name":"Case Studies","item":"https:\/\/catapult.org.uk\/our-work\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Establishing Stevenage as a global leader for cell and gene therapies"}]},{"@type":"WebSite","@id":"https:\/\/catapult.org.uk\/#website","url":"https:\/\/catapult.org.uk\/","name":"The Catapult Network","description":"The Innovate UK Catapult Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/catapult.org.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study\/5306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/types\/case_study"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media\/5307"}],"wp:attachment":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media?parent=5306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/categories?post=5306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/tags?post=5306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}